Remifentanil Negatively Regulates RANKL-Induced Osteoclast Differentiation and Bone Resorption by Inhibiting c-Fos/NFATc1 Expression

[1]  Cheul-Hong Kim,et al.  Effects of Remifentanil Preconditioning on Osteoblasts under Hypoxia-Reoxygenation Condition , 2015, International journal of medical sciences.

[2]  Jiake Xu,et al.  An overview of the regulation of bone remodelling at the cellular level. , 2012, Clinical biochemistry.

[3]  Y. Soh,et al.  Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. , 2010, European journal of pharmacology.

[4]  Xi Wang,et al.  NFATc1: functions in osteoclasts. , 2010, The international journal of biochemistry & cell biology.

[5]  H. Takayanagi,et al.  Osteoimmunology: Crosstalk Between the Immune and Bone Systems , 2009, Journal of Clinical Immunology.

[6]  M. Ishii,et al.  Osteoclast cell fusion: mechanisms and molecules , 2008, Modern rheumatology.

[7]  Ryan J. Buus,et al.  A Fracture Pain Model in the Rat: Adaptation of a Closed Femur Fracture Model to Study Skeletal Pain , 2008, Anesthesiology.

[8]  A. Cress,et al.  Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer , 2007, Pain.

[9]  Hong-Hee Kim,et al.  Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. , 2006, Biochemical and biophysical research communications.

[10]  Y. Kadono,et al.  Osteoimmunology: interplay between the immune system and bone metabolism. , 2006, Annual review of immunology.

[11]  H. J. Kim,et al.  Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-κB transactivation by RANKL , 2006, Cell Death and Differentiation.

[12]  P. Leprince,et al.  Remifentanil Induces Systemic Arterial Vasodilation in Humans with a Total Artificial Heart , 2004, Anesthesiology.

[13]  Hong-Hee Kim,et al.  Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. , 2003, Biochemical and biophysical research communications.

[14]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[15]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[16]  J. Riancho,et al.  Expression of Opioid Receptors in Osteoblast-Like MG-63 Cells, and Effects of Different Opioid Agonists on Alkaline Phosphatase and Osteocalcin Secretion by These Cells , 2000, Neuroendocrinology.

[17]  R. Mirakhur,et al.  Severe Cardiovascular Depression with Remifentanil , 2000, Anesthesia and analgesia.

[18]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[19]  H. Rosen,et al.  Dual role of osteoblastic proenkephalin derived peptides in skeletal tissues , 1994, Journal of cellular biochemistry.

[20]  J. Cabranes,et al.  Lower Serum Osteocalcin Levels in Pregnant Drug Users and Their Newborns at the Time of Delivery , 1990, Obstetrics and Gynecology.

[21]  E Y Chao,et al.  Internal remodeling of periosteal new bone during fracture healing , 1990, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[22]  O. Paar,et al.  [Modification of human osteoblasts by various analgesics]. , 2002, Der Unfallchirurg.

[23]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[24]  D. Baksi.  Fracture healing. , 1980, Journal of the Indian Medical Association.